Transforming Hematological
Diagnostics with AI
Join the Revolution in Medical Diagnostics
Embrace the future of healthcare with Cancilico’s cutting-edge AI technology. Our solutions are designed to enhance accuracy and efficiency in diagnosing hematological cancers. Experience the power of innovation in medical diagnostics.
Our Startup Vission
Cancilico: Pioneering AI in Hematological Healthcare
At Cancilico, we are committed to revolutionizing the field of hematological diagnostics. Our vision is to harness the potential of artificial intelligence to streamline and improve the accuracy of critical diagnostic processes. With a focus on morphological differentiation of bone marrow smears, our technology aims to bring a new era of precision and speed to the diagnosis of hematological cancers. In an industry where every second counts, our solutions promise to deliver faster, more reliable results, aiding clinicians in making timely and informed decisions, thereby enhancing patient care and outcomes.
MyeloAID and AI services
Introducing MyeloAID
The Future of Diagnostics
MyeloAID:
Our flagship AI software, MyeloAID, automates the classification and counting of cells in bone marrow samples. Utilizing advanced AI algorithms,MyeloAID provides a rapid and accurate analysis of cell types, creating a detailed myelogram in minutes. This innovation not only increases diagnostic precision but also significantly reduces the time and labor traditionally required in hematological examinations.
Cancilico's AI Suite
Beyond MyeloAID, our suite of AI-driven solutions is tailored to address various challenges in medical diagnostics. From cloud-based platforms for research to specialized algorithms for rare cell type identification, our services are designed to integrate seamlessly with existing medical infrastructure, offering a low barrier to entry with high-value outcomes. Our commitment to continuousimprovement and regulatory compliance ensures that our products not only meet but exceed the evolving needs of the medical community.
Partners
News
Exploring the Future of AI in Medicine: Cancilico’s Experience at the “AI-in-Medicine” Conference
In the rapidly evolving world of medical technology, Cancilico recently had the opportunity to attend the prestigious "AI-in-Medicine" conference, a gathering that showcases the latest advancements and discussions in the field of artificial intelligence in healthcare....
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
The recent years have brought a lot of advancements in understanding leukemia biology due to comprehensive studies investigating molecular alterations. Risk stratification, however, is still largely restricted to simplistic decision-making models based on singular...
Supervised Learning predicts therapeutic success in acute myeloid leukemia
Achievement of complete remission signifies a crucial milestone in the therapy of acute myeloid leukemia (AML) while refractory disease is associated with dismal outcomes. Hence, accurately identifying patients at risk is essential to tailor treatment concepts...
